| First Author | Gu S | Year | 2018 |
| Journal | Leukemia | Volume | 32 |
| Issue | 1 | Pages | 203-213 |
| PubMed ID | 28804122 | Mgi Jnum | J:253876 |
| Mgi Id | MGI:6110793 | Doi | 10.1038/leu.2017.250 |
| Citation | Gu S, et al. (2018) SHP2 is required for BCR-ABL1-induced hematologic neoplasia. Leukemia 32(1):203-213 |
| abstractText | BCR-ABL1-targeting tyrosine kinase inhibitors (TKIs) have revolutionized treatment of Philadelphia chromosome-positive (Ph(+)) hematologic neoplasms. Nevertheless, acquired TKI resistance remains a major problem in chronic myeloid leukemia (CML), and TKIs are less effective against Ph(+) B-cell acute lymphoblastic leukemia (B-ALL). GAB2, a scaffolding adaptor that binds and activates SHP2, is essential for leukemogenesis by BCR-ABL1, and a GAB2 mutant lacking SHP2 binding cannot mediate leukemogenesis. Using a genetic loss-of-function approach and bone marrow transplantation models for CML and BCR-ABL1(+) B-ALL, we show that SHP2 is required for BCR-ABL1-evoked myeloid and lymphoid neoplasia. Ptpn11 deletion impairs initiation and maintenance of CML-like myeloproliferative neoplasm, and compromises induction of BCR-ABL1(+) B-ALL. SHP2, and specifically, its SH2 domains, PTP activity and C-terminal tyrosines, are essential for BCR-ABL1(+), but not WT, pre-B-cell proliferation. The mitogen-activated protein kinase kinase (MEK) / extracellular signal-regulated kinase (ERK) pathway is regulated by SHP2 in WT and BCR-ABL1(+) pre-B cells, but is only required for the proliferation of BCR-ABL1(+) cells. SHP2 is required for SRC family kinase (SFK) activation only in BCR-ABL1(+) pre-B cells. RNAseq reveals distinct SHP2-dependent transcriptional programs in BCR-ABL1(+) and WT pre-B cells. Our results suggest that SHP2, via SFKs and ERK, represses MXD3/4 to facilitate a MYC-dependent proliferation program in BCR-ABL1-transformed pre-B cells. |
